Union Budget 2013: Pharma sector expects sweet pill in upcoming Budget

Recently RBI has reduced its GDP growth forecast for FY13 to 5.5 percent. This clearly indicates a slowdown in the economy which can be attributed to higher interest rates, rising input costs and constrained investments.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney SME Special
moneycontrol.com

Home » News » Economy

Feb 25, 2013, 08.27 PM | Source: Moneycontrol.com

Union Budget 2013: Pharma sector expects sweet pill in upcoming Budget

Recently RBI has reduced its GDP growth forecast for FY13 to 5.5 percent. This clearly indicates a slowdown in the economy which can be attributed to higher interest rates, rising input costs and constrained investments.

Like this story, share it with millions of investors on M3

Union Budget 2013: Pharma sector expects sweet pill in upcoming Budget

Recently RBI has reduced its GDP growth forecast for FY13 to 5.5 percent. This clearly indicates a slowdown in the economy which can be attributed to higher interest rates, rising input costs and constrained investments.

Post Your Comments

Share Cancel

In this Budget we expect government to bring down taxes and duties on the life saving drugs and active pharmaceutical ingredients (API) in-turn providing an impetus to growth

- Dr B. Arvind Shah (CEO & MD)

Dr B. Arvind Shah
Arvind Remedies

Recently RBI has reduced its GDP growth forecast for FY13 to 5.5 percent. This clearly indicates a slowdown in the economy which can be attributed to higher interest rates, rising input costs and constrained investments. Pharma sector's performance in FY13 has been stable. However, we believe that sector has immense potential to grow if in the upcoming Budget government comes out with strong measures to reinstate confidence.

In this Budget we expect government to bring down taxes and duties on the life saving drugs and active pharmaceutical ingredients (API) in-turn providing an impetus to growth. Currently, a weighted tax deduction of 200 percent is available for the R&D expenditure undertaken in an in house facility, we expect this to be increase it to 250-300 percent and also expect it to be extended to expenditure incurred on the external R&D undertaken.

Pricing of pharma products is of key importance to consumers and the companies. Hence in order to make life saving drugs at affordable to people we believe that reduction or abolishing the excise duty will. Apart from this increase in the healthcare Budget will provide the required growth to the industry.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Union Budget 2013: Pharma sector expects sweet pill in upcoming Budget

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login